[1] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南. 实用肝脏病杂志,2017,20(6):后插1-18. [2] Navarro VJ,Barnhart H,Bonkovsky HL,et a1.Liver injure from herbals and dietary supplements in the U.S.drug-induced Liver injure Network.Hepatology,2014,60:1399-1408. [3] Navarro VJ,Senior JR.Drug-related hepatotoxicity. N Engl J Med,2006,354(7):731-739. [4] Lewis JH,Zimmerman HJ.Drug-induced autoimmune liver disease. In:Krawitt EL,Wiesner RH,Nishioka K,eds. Autoimmune Liver Diseases. 2nd ed. Amsterdam:Elsevier,1998:627-649. [5] Liu ZX,Kaplowitz N.Immune-mediated drug-induced liver disease. Clin Liver Dis,2002,6:755-774. [6] Danan G,Benichou C.Causality assessment of adverse reactions to drugs:A novel method based on the conclusions of international consensus meetings:application to drug-induced liver injuries.J Clin Epidemiol,1993,46:1323-1330. [7] Hennes EM,Zeniya M,Czaja AJ,et al.Simplified criteria for the diagnosis of autoimmune hepatitis.Hepatology,2008,48:169-176. [8] Li L,Jiang W,Wang JY.Clinical analysis of 275 cases of acute drug-induced liver disease. Front Med China,2007,1(1):58-61. [9] Fontana R J,Seeff L B,Andrade R J,et al.Standardization of nomenclature and causality assessment in drug-induced liver injury:summary of a clinical research workshop. Hepatology,2010,52(2):730-742. [10] Watkins PB,Seligman PJ,Pears JS,et al.Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology,2008,48:1680-1689. [11] Manns MP,Czaja AJ,Gorham JD,et al.Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology,2010,51:2193-2213. [12] Czaja AJ.Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol,2009,3:269-291. [13] 刘燕敏,闫惠平,韩莹,等. 急性及慢性药物性肝损害患者肝功能及自身抗体检测的临床意义. 中华肝脏病杂志,2010,12(1):37-40. [14] Czaja AJ.Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol,2009,51:161-167. [15] Montano-Loza AJ,Carpenter HA,Czaja AJ.Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol,2007,102:1005-1012. [16] Bjornsson E,Talwalkar J,Treeprasertsuk S,et al.Drug-induced autoimmune hepatitis:clinical characteristics and prognosis. Hepatology,2010,51(6):2040-2048. [17] Suzuki A,Brunt EM,Kleiner DE,et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis vs. drug-induced liver injury. Hepatology,2011,54:931-939. [18] Bjornsson ES,Bergmann O,Jonasson JG,et al.Drug-induced autoimmune hepatitis:Response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol,2017,15:1635-1636. [19] Kuzu UB,oztas E,Turhan N,et al. Clinical and histological features of idiosyncratic liver injury:Dilemma in diagnosis of autoimmune hepatitis. Hepatol Res,2016,46:277-291. [20] 中华医学会.糖皮质激素类药物临床应用指导原则.中华内分泌代谢杂志,2012,28:1-256. [21] Wiegard C,Frenzel C,Herkel J,et al.Murine liver antigen presenting cells control suppressor activity of CD4+CD25+ regulatory T cells. Hepatology,2005,42:193-199. [22] Longhi MS,Ma Y,et al.Boqdanos DP.Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol,2004,41:31-37. |